Chronic ebv infection in clinical practice: what should be considered when diagnosing

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Epstein–Barr virus (EBV) is ubiquitous pathogen, founded in 95% of population. After primary infection, EBV realizes life-long latency in B-lymphocytes and saliva. Periodic reactivation is not clinically important. Detection of IgG, EBV DNA in saliva, urine and in blood (less than 100 copies/ml) are the signs of latent infection, the treatment is unnecessary. In rare cases in immunocompromised and/or transplant patients clinically important reactivation occurs with development of chronic active form of EBV, lymphoproliferative disorders or malignization. The treatment of chronic active forms of EBV is vitally necessary.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Mikhail Nikolskiy

I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia

Хат алмасуға жауапты Автор.
Email: nicolm@inbox.ru

PhD in Medical Sciences, assistant at the Department of pediatrics, I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia

Ресей, 197022, Saint Petersburg,6/8 Lva Tolstogo Str.

Dmitry Lioznov

I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia; A.A. Smorodintsev Research Institute of Influenza of the Ministry of Healthcare of Russia, Saint Petersburg

Email: dmitry.lioznov@influenza.spb.ru

MD, professor, director of A.A. Smorodintsev Research Institute of Influenza of the Ministry of Healthcare of Russia, head of the Department of infectious diseases and epidemiology, I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia

Ресей, 197022, Saint Petersburg,15/17 Professora Popova Str.

Andrey Malyavin

A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia

Email: maliavin@mail.ru

MD, professor, professor of the Department of phthisiology and pulmonology, A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia

Ресей, 127473, Moscow,20 Delegatskaya Str.

Әдебиет тізімі

  1. Ракитянская И.А., Рябова Т.С., Тоджибаев У.А., Калашникова А.А. Новые подходы в лечении хронической вирусной Эпштейна–Барр инфекции. Архив акушерства и гинекологии имени В.Ф. Снегирева. 2019; 6(1): 19–26. [Rakityanskaya I.A., Ryabova T.S., Todzhibaev U.A., Kalashnikova A.A. New approaches in the treatment of chronic viral Epstein-Barr infection. Arkhiv akusherstva i ginekologii imeni V.F. Snegireva = V.F. Snegirev Archives of Obstetrics and Gynecology. 2019; 6(1): 19–26 (In Russ.)]. https://dx.doi.org/10.18821/2313-8726-2019-6-1-19-26. EDN: YYBIGD.
  2. Дубинская Г.М., Коваль Т.И., Боднарь В.А. с соавт. Подходы к диагностике хронических форм Эпштейна–Барр-вирусной инфекции у взрослых на основе комплексной оценки клинико-иммунологических показателей. Клиническая инфектология и паразитология. 2012; (3–4): 55–67. [Dubynskya G.M., Koval T.I., Bodnar V.A. et al. The approaches to diagnosis of chronic forms of epstein-barr virus infections in adults based on comprehensive evaluation of clinical and immunological indicators. Klinicheskaya infektologiya and parazitologiya = Clinical Infectology and Parasitology. 2012; (3–4): 55–67 (In Russ.)]. EDN: PYZKCD.
  3. Кадаева С.Г. Показатели реактивации хронической инфекции вируса Эпштейн–Барр. Вестник молодого ученого. 2015; 9(2): 32–34. [Kadaeva S.G. Indicators of reactivation of chronic infection of Epstein–Barr virus. Vestnik molodogo uchenogo = Journal of Young Scientist. 2015; 9(2): 32–34(In Russ.)]. EDN: UBIMXP.
  4. Нестерова И.В., Халтурина Е.О. Алгоритм клинико-иммунологической и лабораторной диагностики атипичной хронической активной Эпштейн–Барр герпесвирусной инфекции. Российский иммунологический журнал. 2018; 12(2): 170–177. [Nesterova I.V., Khalturina E.O. Clinical, immunological criteria and laboratory markers of atypical chronic active infection caused by the Epstein–Barr virus. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology. 2018; 12(2): 170–177 (In Russ.)]. https://dx.doi.org/10.7868/S1028722118020089. EDN: RSXTPR.
  5. Перадзе Х.Д. Клинико-лабораторные особенности острых и хронических форм Эпштейна–Барр вирусной инфекции (инфекционного мононуклеоза) у подростков и лиц молодого возраста. Специальность 14.01.09 «Инфекционные болезни»: диссертация на соискание ученой степени кандидата медицинских наук. Санкт-Петербург. 2004; 134 с. [Peradze Kh.D. Clinical and laboratory features of acute and chronic forms of Epstein–Barr viral infection (infectious mononucleosis) in adolescents and young people. Specialty 14.01.09 «Infectious diseases»: Dissertation for the degree of Candidate of Medical Sciences. Saint Petersburg. 2004; 134 pp. (In Russ.)].
  6. Триско А.А. Оптимизация диагностических и прогностических критериев инфекционного мононуклеоза Эпштейна–Барр вирусной этиологии у взрослых. Специальность 14.01.09 «Инфекционные болезни»: диссертация на соискание ученой степени кандидата медицинских наук. Краснодар. 2017; 167 с. [Trisko A.A. Optimization of diagnostic and prognostic criteria of infectious mononucleosis of Epstein–Barr viral etiology in adults. Specialty 14.01.09 «Infectious diseases»: Dissertation for the degree of Candidate of Medical Sciences. Krasnodar. 2017; 167 pp. (In Russ.)].
  7. Блохина Е.Б. Роль латентной инфекции, вызванной вирусом Эпштейна–Барр, в развитии лимфопролиферативных заболеваний. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2003; 2(3): 65–70. [BIokhina E.B. Role of latent infection induced by Epstein–Barr virus in development of lymphoproliferative diseases. Voprosy gematologii/onkologii i immunopatologi v pediatrii = Pediatric Hematology/Oncology and Immunopathology. 2003; 2(3): 65–70 (In Russ.)]. EDN: HFKAOH.
  8. Мазус А.И., Цыганова Е.В., Глухоедова Н.В., Жиленкова А.С. Эпштейна–Барр вирусная инфекция: от инфекционного мононуклеоза до лимфопролиферативного заболевания. Терапия. 2021; 7(2): 112–122. [Mazus A.I., Tsyganova E.V., Glukhoedova N.V., Zhilenkova A.S. Epstein–Barr virus infection: From infectious mononucleosis to lymphoproliferative disorder. Terapiya = Therapy. 2021; 7(2): 112–122 (In Russ.)]. https://dx.doi.org/10.18565/therapy.2021.2.112-122. EDN: QTYTYI.
  9. Kimura H., Ito Y., Kawabe S. et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: Prospective analysis of 108 cases. Blood. 2012; 119(3): 673–86. https://dx.doi.org/10.1182/blood-2011-10-381921.
  10. Ceraulo A.S., Bytomski J.R. Infectious mononucleosis management in athletes. Clin Sports Med. 2019; 38(4): 555–61. https://dx.doi.org/10.1016/j.csm.2019.06.002.
  11. Fugl A., Andersen C.L. Epstein–Barr virus and its association with disease – A review of relevance to general practice. BMC Fam Pract. 2019; 20(1): 62. https://dx.doi.org/10.1186/s12875-019-0954-3.
  12. Викулов Г. Эпштейна–Барр вирусная инфекция: особенности патогенеза и ассоциация с первичным иммунодефицитом. Врач. 2016; (12): 76–81. [Vikulov G. Epstein–Barr virus infection: Pathogenesis and association with primary immunodeficiency: Analysis of clinical cases. Vrach = The Doctor. 2016; (12): 76–81 (In Russ.)]. EDN: XWPUSB.
  13. De Paschale M., Clerici P. Serological diagnosis of Epstein–Barr virus infection: Problems and solutions. World J Virol. 2012; 1(1): 31–43. https://dx.doi.org/10.5501/wjv.v1.i1.31.
  14. Torre D., Tambini R. Acyclovir for treatment of infectious mononucleosis: A meta-analysis. Scand J Infect Dis. 1999; 31(6): 543–47. https://dx.doi.org/10.1080/00365549950164409.
  15. Murata T., Sugimoto A., Inagaki T. et al. Molecular basis of Epstein–Barr virus latency establishment and lytic reactivation. Viruses. 2021; 13(12): 2344. https://dx.doi.org/10.3390/v13122344.
  16. Holden D.W., Gold J., Hawkes C.H. et al. Epstein Barr virus shedding in multiple sclerosis: Similar frequencies of EBV in saliva across separate patient cohorts. Mult Scler Relat Disord. 2018; 25: 197–19. https://dx.doi.org/10.1016/j.msard.2018.07.041.
  17. Crowley A., Connell J., Schaffer K. et al. Is there diagnostic value in detection of immunoglobulin g antibodies to the Epstein-Barr virus early antigen? Biores Open Access. 2012; 1(6): 291–96. https://dx.doi.org/10.1089/biores.2012.0274.
  18. Niller H.H., Bauer G. Epstein–Barr virus: Clinical diagnostics. Methods Mol Biol. 2017; 1532: 33–55. https://dx.doi.org/10.1007/978-1-4939-6655-4_2.
  19. Worth A., Conyers R., Cohen J. et al. Pre-emptive rituximab based on viraemia and T cell reconstitution: A highly effective strategy for the prevention of Epstein–Barr virus-associated lymphoproliferative disease following stem cell transplantation. Br J Haematol. 2011; 155(3): 377–85. https://dx.doi.org/10.1111/j.1365-2141.2011.08855.x.
  20. Жуков Н.В., Рабаева Л.Л. Назофарингеальная карцинома у детей и подростков. Обзор литературы и собственные данные. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2022; 21(2): 66–77. [Zhukov N.V., Rabaeva L.L. Nasopharyngeal carcinoma in children and adolescents: A literature review and our own data. Voprosy gematologii/onkologii i immunopatologi v pediatrii = Pediatric Hematology/Oncology and Immunopathology. 2022; 21(2): 66–77 (In Russ.)]. https://dx.doi.org/10.24287/1726-1708-2022-21-2-66-77. EDN: JDJFZW.
  21. Guerrero-Ramos A., Patel M., Kadakia K. et al. How I treat T-cell chronic active Epstein–Barr virus disease. Blood. 2018; 131(26): 2899–905. https://dx.doi.org/10.1182/blood-2018-03-785931.
  22. Якушина С.А., Кистенева Л.Б., Чешик С.Г. Принципы терапии хронической Эпштейна–Барр вирусной инфекции и ассоциированных заболеваний. Российский вестник перинатологии и педиатрии. 2019; 64(2): 38–46. [Yakushyna S.A., Kisteneva L.B., Cheshyk S.G. Principles of the treatment of CHRONIC Epstein–Barr virus infection and associated diseases. Rossiyskiy vestnik perinatologii i pediatrii = Russian Bulletin of Perinatology and Pediatrics. 2019; 64(2): 38–46 (In Russ.)]. https://dx.doi.org/10.21508/1027-4065-2019-64-2-38-46. EDN: ZFANNZ.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>